{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:36:51Z","timestamp":1771364211322,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,11,26]],"date-time":"2014-11-26T00:00:00Z","timestamp":1416960000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s40268-014-0067-3","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T17:40:47Z","timestamp":1417542047000},"page":"309-314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Stability and Recovery of DIFICID\u00ae (Fidaxomicin) 200-mg Crushed Tablet Preparations from Three Delivery Vehicles, and Administration of an Aqueous Dispersion via Nasogastric Tube"],"prefix":"10.1007","volume":"14","author":[{"given":"Anna","family":"Tousseeva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Derek","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Redell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelley","family":"Capurso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Andrew","family":"DeRyke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,26]]},"reference":[{"key":"67_CR1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","volume":"31","author":"SH Cohen","year":"2010","unstructured":"Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431\u201355.","journal-title":"Infect Control Hosp Epidemiol."},{"key":"67_CR2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","volume":"364","author":"TJ Louie","year":"2011","unstructured":"Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Eng J Med. 2011;364:422\u201331.","journal-title":"N Eng J Med."},{"key":"67_CR3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","volume":"12","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12:281\u20139.","journal-title":"Lancet Infect Dis."},{"key":"67_CR4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","volume":"45","author":"FA Zar","year":"2007","unstructured":"Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile\u2013associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302\u20137.","journal-title":"Clin Infect Dis."},{"issue":"Suppl 6","key":"67_CR5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1469-0691.12046","volume":"18","author":"CP Kelly","year":"2012","unstructured":"Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18(Suppl 6):21\u20137.","journal-title":"Clin Microbiol Infect."},{"key":"67_CR6","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1056\/NEJMra0707500","volume":"359","author":"CP Kelly","year":"2008","unstructured":"Kelly CP, LaMont JT. Clostridium difficile\u2014more difficult than ever. N Engl J Med. 2008;359:1932\u201340.","journal-title":"N Engl J Med."},{"key":"67_CR7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1086\/659156","volume":"32","author":"BA Miller","year":"2011","unstructured":"Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011;32:387\u201390.","journal-title":"Infect Control Hosp Epidemiol."},{"key":"67_CR8","unstructured":"Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009: Statistical Brief #124. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville: US Agency for Healthcare Research and Quality; 2012. http:\/\/www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb124.pdf . Accessed 14 Apr 2014."},{"key":"67_CR9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.12135","volume":"1291","author":"P Sears","year":"2013","unstructured":"Sears P, Ichikawa Y, Ruiz N, Gorbach S. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic. Ann NY Acad Sci. 2013;1291:33\u201341.","journal-title":"Ann NY Acad Sci."},{"issue":"Suppl 2","key":"67_CR10","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1093\/cid\/cis337","volume":"55","author":"P Sears","year":"2012","unstructured":"Sears P, Crook DW, Louie TJ, Miller MA, Weiss K. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis. 2012;55(Suppl 2):S116\u201320.","journal-title":"Clin Infect Dis."},{"issue":"4","key":"67_CR11","first-page":"375","volume":"26","author":"E Maseda","year":"2013","unstructured":"Maseda E, Hernandez-Gancedo C, Lopez-Tofi\u00f1o A, Suarez-de-la Rica A, Garcia-Bujalance S, Gilsanz F. Use of fidaxomicin through a nasogastric tube for the treatment of septic shock caused by Clostridium difficile infection in a patient with oral cancer admitted to the Surgical Critical Care Unit. Rev Esp Quimioter. 2013;26(4):375\u20137.","journal-title":"Rev Esp Quimioter."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-014-0067-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-014-0067-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-014-0067-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T18:12:31Z","timestamp":1551204751000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-014-0067-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,26]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["67"],"URL":"https:\/\/doi.org\/10.1007\/s40268-014-0067-3","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,26]]}}}